Investors
Information Disclosure
-
FINAL DIVIDEND FOR 20232024.03.28
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF “IOPROMIDE INJECTION”2024.03.25
-
VOLUNTARY ANNOUNCEMENT - UPDATE ON DEVELOPMENT PROGRESS OF MASH PRODUCTS "LANIFIBRANOR" AND "TQA2225"2024.03.15
-
VOLUNTARY ANNOUNCEMENT - DATA OF PHASE II CLINICAL STUDY OF KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" WILL BE PRESENTED AT 2024 AACR2024.03.13
-
VOLUNTARY ANNOUNCEMENT - DATA OF 5 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES" AND "TQB2916 (CD40 AGONIST)" WILL BE PRESENTED AT 2024 AACR2024.03.11
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 20242024.03.01
-
NOTIFICATION OF BOARD MEETING2024.03.01
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULES AND ANTI PD-L1 "BENMELSTOBART (TQB2450 INJECTION)"2024.02.28